Triacetin (Glyceryl Triacetate): A Comprehensive Reference
1. Identity and Chemical Characterization
Names and Synonyms
Triacetin is also known as glyceryl triacetate, glycerol triacetate, glycerin triacetate, glycerine triacetate, triacetyl glycerine, acetin-tri, 1,2,3-triacetoxypropane, 1,2,3-propanetriol triacetate, 1,2,3-propanetriyl triacetate, and acetic-1,2,3-prepanetriyl ester. Common trade names include Enzactin, Fungacetin, Glyped, Kesscoflex TRA, and Vanay. It is assigned CAS Registry Number 102-76-1, an E number of E1518, and Australian approval code A1518.
Chemical Structure and Molecular Identity
Triacetin is a clear, colorless, and odorless liquid. Its chemical formula, C9H14O6, reflects a structure where three acetate groups are bonded to a glycerol backbone, making it a triglyceride that is both simple and versatile. It is a chemical compound obtained from the complete esterification of glycerol with acetic acid. Being the smallest triacylglyceride (TAG), it has intermediate chemical properties between glycerol and fats.
It is a colorless, viscous, and odorless liquid with a high boiling point and a low melting point. It has a mild, sweet taste in concentrations lower than 500 ppm, but may appear bitter at higher concentrations. The compound is soluble in water and miscible with alcohol and most organic solvents. It is miscible with ethanol, ether, benzene, chloroform and other organic solvents, soluble in acetone, and insoluble in mineral oil. It is slightly soluble in water, with a solubility of 5.9 g/100 mL at 25°C.
Natural Occurrence
Triacetin is a colorless, oily liquid that, although most often synthesized, can be found naturally in cod-liver oil, butter, and other fats. It has also been identified naturally in papaya.
Synthesis
The synthesis of triacetin primarily involves the esterification of glycerol with acetic acid. This reaction is typically catalyzed by acidic or basic catalysts and can be conducted under reflux to ensure complete conversion. The process may vary slightly depending on the desired purity and yield, with industrial synthesis often scaling up this reaction under controlled conditions.
Physical and Pharmacopeial Specifications
Triacetin has a CAS Number of 102-76-1, and appears as a colorless, viscous and odorless (or slightly fatty-odored) liquid. The assay specification requires not less than 98.5% of C9H14O6. The refractive index lies between 1.429 and 1.431 at 25°C, and the specific gravity is between 1.154 and 1.158. It is listed in the United States Pharmacopeia (USP), the European Pharmacopoeia (Ph. Eur./EP), and the British Pharmacopoeia (BP).
Common Grades and Preparations
Triacetin is reported to function as a cosmetic biocide, plasticizer, and solvent in cosmetic formulations, at concentrations ranging from 0.8% to 4.0%. It is used as an excipient in pharmaceutical products, where it is used as a humectant, a plasticizer, and as a solvent. Triacetin was marketed from 1956 under the trade name of Fungacetin, in the form of an aerosol, a cream, or a powder to be applied to the skin.
2. Historical and Traditional Use
Triacetin is a triester of glycerin and acetic acid. It has been used for over 75 years for a wide range of uses, including cosmetic biocide (most often as a fungicide), plasticizer, solvent in cosmetic formulas, food additive (as a flavoring agent and adjuvant), and as a binder for combustible material in solid-rocket propellants.
Triacetin does not have a deep traditional herbal or botanical medicine history in the sense that most botanical supplements do. Its documented use is primarily industrial and pharmaceutical, dating from the mid-twentieth century onward. Its antimycotic activity, linked to the gradual release of acetic acid by hydrolysis of triacetin by the esterases of microscopic fungi responsible for mycoses, was formally exploited when triacetin was marketed from 1956 under the trade name of Fungacetin, in the form of an aerosol, a cream, or a powder to be applied to the skin.
In the late 1960s, triacetin was considered a possible source of long-term dietary energy for space missions, after being tested on rats. It has been considered as a possible source of food energy in artificial food regeneration systems on long space missions. It is believed to be safe to derive over half of one's dietary energy from triacetin.
In a 1994 report published by five major cigarette companies, triacetin was among the 599 additives for cigarettes. Its most significant industrial application lies in the manufacturing of cigarette filters, where it is applied to cellulose acetate tow. This process imbues the filter rods with the necessary flexibility and hardness, ensuring they meet stringent performance standards. The application of triacetin in cigarette filters involves precise control of its concentration, typically between 6% and 9% of the total filter weight, to achieve optimal results.
3. Key Constituents, Active Compounds, and Mechanisms of Action
Chemical Constituents
Triacetin is itself the active compound of interest. It is not derived from a complex botanical matrix and does not contain a range of secondary metabolites. Its molecular formula is C9H14O6, with the structural representation (CH3COOCH2)2CHOCOCH3. It is a triglyceride obtained by acetylation of the three hydroxy groups of glycerol.
Metabolic Hydrolysis: The Primary Mechanism
Triacetin is absorbed following ingestion and metabolized like other shorter-chain triglycerides. Several studies confirmed that triacetin is hydrolyzed to glycerol and acetic acid by digestive enzymes, particularly lipases, liver or plasma carboxyesterases. Triacetin infused in dogs undergoes intravascular hydrolysis, and the majority of the resulting acetate is oxidized nearly quantitatively rather than reesterified or elongated, as is the case with short- and medium-chain fatty acids.
Antifungal Mechanism
The fungistatic activity of triacetin results from its hydrolysis by fungal esterases to acetic acid. The activity of triacetin is a result of the acetic acid released by hydrolysis of the compound by esterases present in the skin. Acid release is a self-limiting process because the esterases are inhibited below pH 4. Esterases in fungi or in serum act at pH greater than 4 to slowly release acetic acid in situ. The extent of hydrolysis is automatically limited by increased acidity and lowering of pH.
Acetate Donor and Neurological Mechanism
Glyceryl triacetate (GTA) is a short-chain triglyceride with three acetate moieties on a glycerol backbone and has proven an effective acetate precursor. Canavan disease is a fatal genetic neurodegenerative disorder caused by mutations in the gene for aspartoacylase, an enzyme that hydrolyzes N-acetylaspartate (NAA) into L-aspartate and acetate. Because aspartoacylase is localized in oligodendrocytes, and NAA-derived acetate is incorporated into myelin lipids, it has been hypothesized that an acetate deficiency in oligodendrocytes is responsible for the pathology in Canavan disease.
Epigenetic and Oncological Mechanisms (Preclinical)
Cancer is associated with global hypoacetylation and aerobic glycolysis. Research has demonstrated that aspartoacylase, the enzyme that catabolizes N-acetyl-L-aspartate, the primary storage form of acetate in the brain, is reduced in glioma tumors. In preclinical cell and animal studies, triacetin has been investigated as an acetate donor capable of reversing hypoacetylation states in tumor cells.
Plasticizing Mechanism in Pharmaceutical Applications
Triacetin is extensively used as a plasticizer in cellulose-based plastics, providing flexibility and durability to products such as film coatings and tool handles. In the pharmaceutical industry, triacetin serves as a solvent and excipient, aiding in the formulation of capsules and tablets by enhancing the dissolution of active ingredients and improving their bioavailability.
4. Scientific Evidence by Area of Use
4.1 Antifungal Activity (Dermatophyte Infections)
Biological rationale: Triacetin has fungistatic properties and has been used in the topical treatment of minor dermatophyte infections. The mechanism, as described above, is the enzymatic liberation of acetic acid at the site of infection.
Evidence strength: Clinical use of topical triacetin (sold as Fungacetin/Enzactin) dates to the 1950s, and the compound is recognized as having antifungal properties in reference pharmacological literature. However, the available published literature does not include large, placebo-controlled randomized clinical trials specifically evaluating triacetin monotherapy for dermatophyte infections by modern standards. The evidence for topical antifungal use is primarily based on historical clinical application, the established mechanistic basis (acetic acid release), and regulatory recognition rather than on modern prospective RCT data.
4.2 Canavan Disease and Neurological Acetate Supplementation
Background: Canavan disease is a fatal dysmyelinating genetic disorder associated with aspartoacylase deficiency, resulting in decreased brain acetate levels and reduced myelin lipid synthesis in the developing brain. A tolerability study tested glyceryl triacetate (GTA) as a potent acetate precursor, at low doses in two infants diagnosed with Canavan disease, aged 8 and 13 months.
Dosing in the infant clinical study: GTA was given orally to the infants for up to 4.5 and 6 months, starting at 25 mg/kg twice daily, doubling the dose weekly until a maximum of 250 mg/kg was reached. GTA treatment caused no detectable toxicity and the patients showed no deterioration in clinical status.
High-dose safety trial: Intragastric administration of GTA to tremor mice resulted in greatly increased brain acetate levels and improved motor functions. GTA given to infants with Canavan disease at a low dose (up to 0.25 g/kg/day) resulted in no improvement in their clinical status, but also no detectable toxicity.
Preclinical mechanistic data: The concentrations of brain acetate and NAA were determined simultaneously after intragastric administration of GTA. Acetate levels in brain were increased in a dose- and time-dependent manner, with a 17-fold increase observed at 1 to 2 hours in 20- to 21-day-old mice at a dose of 5.8 g/kg GTA.
Evidence strength: Evidence for efficacy in Canavan disease is preliminary and early-phase. The published human data consist of very small-scale tolerability reports (two infants) rather than controlled efficacy trials. Animal studies demonstrate proof-of-concept for acetate delivery to brain tissue, but translation to clinical benefit in humans has not been established.
4.3 Glioma and Brain Cancer (Preclinical Research)
Research has proposed that GTA-mediated acetate supplementation may provide a novel, safe chemotherapeutic adjuvant to reduce the growth of glioma tumors. Levels of N-acetyl-L-aspartate and aspartoacylase, the enzyme responsible for NAA catabolism to generate acetate, are reduced in glioma. A preclinical study sought to test the efficacy of the food additive triacetin as a novel therapy to increase acetate bioavailability in glioma cells. GTA-mediated acetate supplementation may provide a novel, safe chemotherapeutic adjuvant to reduce the growth of glioma tumors, most notably the more rapidly proliferating, glycolytic, and hypoacetylated mesenchymal glioma tumors.
Evidence strength: All available evidence in oncology is preclinical (in vitro and animal models only). No human clinical trials of triacetin as a cancer therapy have been published. This area remains entirely exploratory.
4.4 Pharmaceutical Excipient Use (Film Coating, Drug Delivery)
The plasticizing capabilities of triacetin have been utilized in the synthesis of a biodegradable phospholipid gel system for the dissemination of the cancer drug paclitaxel. In a study, triacetin was combined with paclitaxel, ethanol, a phospholipid, and a medium-chain triglyceride to form a gel-drug complex. This complex was then injected directly into the cancer cells of glioma-bearing mice. The gel slowly degraded and facilitated sustained release of paclitaxel into the targeted glioma cells.
Triacetin is an excipient used as a plasticizer in polymer blends used for the film coating of tablets. This application is well-established and governs the majority of triacetin's pharmaceutical use.
Evidence strength: Triacetin's role as a pharmaceutical excipient (plasticizer, humectant, solvent) is well-established, supported by pharmacopeial monographs (USP, Ph. Eur.) and long-standing regulatory approval.
4.5 Parenteral Nutrition (Animal Studies)
Triacetin is a water-soluble short-chain triglyceride that may also have a role as a parenteral nutrient, according to animal studies. Human data for triacetin as a parenteral nutrition substrate are not available in the published literature.
5. Body Systems and Health Areas Associated with Triacetin
- Integumentary / Dermatological System: In cosmetics and personal-care products, triacetin is used in makeup as well as in nail polish and nail enamel removers. It helps cleanse the skin or prevent odor by destroying or inhibiting the growth of microorganisms. Topical antifungal use for minor dermatophyte infections has been documented since the 1950s.
- Nervous System / Neurological: Canavan disease is caused by mutations in the ASPA gene, coding for aspartoacylase, which breaks down N-acetylaspartate to acetate and aspartic acid. The lack of NAA-degrading enzyme activity leads to excess accumulation of NAA in the brain and deficiency of acetate, which is necessary for myelin lipid synthesis. GTA has been studied as an acetate supplement in this condition.
- Gastrointestinal / Metabolic System: Triacetin is absorbed following ingestion and metabolized like other shorter-chain triglycerides. It is hydrolyzed to glycerol and acetic acid by digestive enzymes, particularly lipases, liver or plasma carboxyesterases.
- Oncological (Research Context): Preclinical research has investigated triacetin's potential to increase histone acetylation and reduce the proliferation of glioma stem-like cells; this area is entirely at the research stage with no clinical applications established.
- Respiratory / Inhalation (Occupational): Triacetin is used as a plasticizer in cigarette filter rods; occupational exposure via inhalation or skin contact in manufacturing has been characterized in safety assessments.
6. Dosage Forms and Reported Dosages
Triacetin is reported to function as a cosmetic biocide, plasticizer, and solvent in cosmetic formulations, at concentrations ranging from 0.8% to 4.0%.
The application of triacetin in cigarette filters involves precise control of its concentration, typically between 6% and 9% of the total filter weight, to achieve optimal results.
In the Canavan disease infant tolerability trial: GTA was given orally to the infants for up to 4.5 and 6 months, starting at 25 mg/kg twice daily, doubling the dose weekly until a maximum of 250 mg/kg was reached.
In a rat developmental/reproductive toxicity study: In a study in which 12 rats/sex received doses of 0 (vehicle; distilled water), 40, 200, and 1000 mg/kg body weight/day triacetin by gavage (males for 44 days from 2 weeks prior to mating and females for 41–48 days from 14 days before mating to day 3 postpartum), no maternal toxicity was observed, and there were no fetotoxic or developmental effects. Both the maternal and developmental no-observable-adverse-effect-level (NOAEL) was established as 1000 mg/kg.
In the OECD acute oral toxicity study: In the oral acute toxicity study in rats (2,000 mg/kg body weight, a limit dose level, OECD TG 401), no mortality occurred and no signs of systemic toxicity were observed during the 14-day observation period. Gross pathology revealed no treatment-related changes at the end of two weeks for both sexes. The LD50 of triacetin in rats by gavage is thus determined to be greater than 2,000 mg/kg body weight.
In preclinical neurological brain acetate studies in mice: Acetate levels in brain were increased in a dose- and time-dependent manner, with a 17-fold increase observed at 1 to 2 hours in 20- to 21-day-old mice at a dose of 5.8 g/kg GTA.
For food additive and general exposure: In a toxicology report from 2002, triacetin and a group of related triglycerides did not represent a hazard to human health based on the anticipated daily intake of 7.8 mg/day/adult, and other available data.
7. Regulatory Status
The US Food and Drug Administration has approved triacetin as a generally recognized as safe (GRAS) food additive and included it in the database according to the opinion from the Select Committee on GRAS Substances (SCOGS). This has prompted the FDA to regard triacetin as a GRAS ingredient with no limitations on its conditions of use other than those in the current Good Manufacturing Practice (GMP), found in Title 21, Part 184.1901 of the Code of Federal Regulations (21 CFR 184.1901).
Triacetin is a common food additive, for instance as a solvent in flavorings, and for its humectant function, with E number E1518 and Australian approval code A1518. The European Commission has also approved it for use as a food additive.
Total daily intake of triacetin does not, in the opinion of the Committee (JECFA), represent a hazard to health, and the establishment of an Acceptable Daily Intake (ADI) in mg/kg body weight is not deemed necessary.
On the basis of the available information, the Cosmetic Ingredient Review (CIR) Expert Panel concluded that triacetin is safe as used in cosmetic formulations. The Expert Panel for Cosmetic Ingredient Safety reviewed updated information that has become available since their original assessment from 2003, along with updated information regarding product types, and frequency and concentrations of use, and reaffirmed their original conclusion that triacetin is safe as a cosmetic ingredient. Limited new data (a developmental/reproductive toxicity screening test and two genotoxicity studies) were identified in the published literature; the results of these newly available studies supported the conclusion reached by the Expert Panel in the original review.
8. Safety Considerations and Interactions
General Toxicological Profile
Triacetin was not toxic to animals in acute oral or dermal exposures, nor was it toxic in short-term inhalation or parenteral studies, and subchronic feeding and inhalation studies. According to the FDA, triacetin has been found to be non-toxic in long-term feeding tests in rats at levels that were several orders of magnitude greater than those to which consumers are exposed.
Skin and Eye Irritation
Triacetin was, at most, slightly irritating to guinea pig skin. However, in one study, it caused erythema, slight edema, alopecia, and desquamation, and did cause some irritation in rabbit eyes. Triacetin was not sensitizing in guinea pigs. Triacetin was not an irritant or a sensitizer in a clinical maximization study, and only very mild reactions were seen in a Duhring-chamber test using a 50% dilution. In humans, triacetin reportedly has caused ocular irritation but no injury.
Mutagenicity and Reproductive Toxicity
Triacetin was not mutagenic. Although there were no available reproductive and developmental toxicity data at the time of the original review, triacetin was quickly metabolized to glycerol and acetic acid, and these chemicals were not developmental toxins. Subsequent studies confirmed this profile: in a study in which rats received doses of 0, 40, 200, and 1000 mg/kg body weight/day triacetin by gavage, no maternal toxicity was observed, and there were no fetotoxic or developmental effects.
Tumor Promotion: Theoretical Concern and Resolution
Reports of 1,2-glyceryl diesters, which may be present in triacetin, affecting cell growth and proliferation raised the possibility of hyperplasia and/or tumor promotion. The Cosmetic Ingredient Review (CIR) Expert Panel concluded, however, that the effects of 1,2-glyceryl diesters on cell growth and proliferation require longer ester chains on the glycerin backbone than are present when acetic acid is esterified with glycerin, as in triacetin.
Occupational and Specific Exposure Concerns
One case of skin toxicity (allergic contact eczema) due to industrial use in cigarette filter production has been reported. This is notably distinct from typical consumer exposure levels, which are substantially lower.
There is no evidence in the available information on triacetin that demonstrates or suggests reasonable grounds to suspect a hazard to the public when they are used at levels that are now current or that might reasonably be expected in the future.
Metabolic Fate and Interactions
Triacetin is quickly metabolized to glycerol and acetic acid. No pharmacokinetic drug–drug interactions between triacetin (as a food additive or excipient) and pharmaceutical agents have been identified in the reviewed literature. At excipient concentrations in pharmaceutical tablets, systemic exposure to triacetin is extremely low. The principal concern at higher therapeutic doses, such as those studied in Canavan disease, would be the local and systemic effects of acetic acid release; however, as noted above, no toxicity was detected at doses up to 250 mg/kg/day in the infant trial.
Oral Pharmaceutical Excipient Use
Triacetin is used in oral pharmaceutical formulations and is generally regarded as a relatively nontoxic and nonirritant material at the levels employed as an excipient.
References
Go back